製品名:2-cyano-N-(2-isopropyl-4-methyl-3-pyridyl)acetamide

IUPAC Name:2-cyano-N-[4-methyl-2-(propan-2-yl)pyridin-3-yl]acetamide

CAS番号:2397623-38-8
分子式:C12H15N3O
純度:95%+
カタログ番号:CM1018507
分子量:217.27

包装単位 有効在庫 価格(USD) 数量
CM1018507-250mg in stock Əǟǟ
CM1018507-500mg in stock ţǟĜ
CM1018507-1g in stock ǎƏĜ
CM1018507-5g 1-2 Weeks ƏǭŽĜ
CM1018507-10g 1-2 Weeks ŁŽĜĜ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:2397623-38-8
分子式:C12H15N3O
融点:-
SMILESコード:CC(C)C1=NC=CC(C)=C1NC(=O)CC#N
密度:
カタログ番号:CM1018507
分子量:217.27
沸点:
MDL番号:
保管方法:

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Glecirasib
On January 20, Jacobio Pharma presents data of glecirasib in patients with pancreatic cancer and other solid tumors at the 2024 ASCO GI. For second-line and above KRAS G12C mutated pancreatic cancer patients, the confirmed objective response rate (cORR) was 41.9% and the disease control rate (DCR) was 93.5%. Glecirasib is a potential best-in-class KRAS G12C allosteric inhibitor with promising early clinical efficacy. Glecirasib can be used as monotherapy to treat non-small cell lung cancer, colorectal cancer and other solid tumors with the KRAS G12C mutation. Combinations of Glecirasib with SHP2i, EGFRi, or PD-1 antibodies is expected to have synergistic efficacy and overcome acquired drug resistance.

Related Products